Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 97 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $295,000 | -8.4% | 20,468 | -3.9% | 0.00% | 0.0% |
| Q2 2022 | $322,000 | +11.0% | 21,300 | -12.7% | 0.00% | +50.0% |
| Q1 2022 | $290,000 | -26.8% | 24,400 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $396,000 | -57.4% | 24,400 | -25.0% | 0.00% | -57.1% |
| Q3 2021 | $929,000 | – | 32,537 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,757,000 | 9.37% |
| Sofinnova Investments, Inc. | 2,194,278 | $31,641,000 | 1.84% |
| MPM BioImpact LLC | 443,702 | $6,398,000 | 1.52% |
| Artal Group S.A. | 400,000 | $5,768,000 | 0.25% |
| Polar Capital Holdings Plc | 2,531,546 | $36,505,000 | 0.23% |
| ASHFORD CAPITAL MANAGEMENT INC | 101,970 | $1,470,000 | 0.22% |
| Lombard Odier Asset Management (Switzerland) SA | 168,795 | $2,434,000 | 0.21% |
| Soleus Capital Management, L.P. | 87,182 | $1,257,000 | 0.17% |
| Cormorant Asset Management, LP | 150,000 | $2,163,000 | 0.15% |
| Walleye Capital LLC | 437,344 | $6,307,000 | 0.12% |